{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:49:54Z","timestamp":1794966594461,"version":"4.9.1"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Epstein-Barr virus (EBV) contributes to the development of a significant subset of human lymphomas. As a herpes virus, EBV can transition between a lytic state which is required to establish infection and a latent state where a limited number of viral antigens are expressed which allows infected cells to escape immune surveillance. Three broad latency programs have been described which are defined by the expression of viral proteins RNA, with latency I being the most restrictive expressing only EBV nuclear antigen 1 (EBNA1) and EBV-encoded small RNAs (EBERs) and latency III expressing the full panel of latent viral genes including the latent membrane proteins 1 and 2 (LMP1\/2), and EBNA 2, 3, and leader protein (LP) which induce a robust T-cell response. The therapeutic use of EBV-specific T-cells has advanced the treatment of EBV-associated lymphoma, however this approach is only effective against EBV-associated lymphomas that express the latency II or III program. Latency I tumors such as Burkitt lymphoma (BL) and a subset of diffuse large B-cell lymphomas (DLBCL) evade the host immune response to EBV and are resistant to EBV-specific T-cell therapies. Thus, strategies for inducing a switch from the latency I to the latency II or III program in EBV+ tumors are being investigated as mechanisms to sensitize tumors to T-cell mediated killing. Here, we review what is known about the establishment and regulation of latency in EBV infected B-cells, the role of EBV-specific T-cells in lymphoma, and strategies to convert latency I tumors to latency II\/III.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1342455","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T23:26:27Z","timestamp":1708644387000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Targeting latent viral infection in EBV-associated lymphomas"],"prefix":"10.3389","volume":"15","author":[{"given":"Isabella Y.","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Giulino-Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951001)76:7<1245::aid-cncr2820760723>3.0.co;2-d","article-title":"The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt\u2019s lymphoma from Egypt: epidemiologic correlations","volume":"76","author":"Anwar","year":"1995","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ijc.11443","article-title":"Geographic variation in Epstein-Barr virus-associated Burkitt\u2019s lymphoma in children from Brazil","volume":"108","author":"Klumb","year":"2004","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid","article-title":"EBV in hodgkin lymphoma","volume":"1","author":"Massini","year":"2009","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B4","article-title":"Epstein-Barr virus-associated gastric adenocarcinoma","volume":"140","author":"Shibata","year":"1992","journal-title":"Am J Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0270","article-title":"Epstein-Barr virus infection and nasopharyngeal carcinoma","volume":"372","author":"Tsao","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-22822-8_13","article-title":"The role of EBV in the pathogenesis of diffuse large B cell lymphoma","volume":"390","author":"Healy","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.20001","article-title":"Nodal EBV+ cytotoxic T-cell lymphoma: A literature review based on the 2017 WHO classification","volume":"60","author":"Kato","year":"2020","journal-title":"J Clin Exp Hematop"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.10.1673","article-title":"Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus","volume":"5","author":"List","year":"1987","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012513-104656","article-title":"Gammaherpesviruses and lymphoproliferative disorders","volume":"9","author":"Cesarman","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-022-03414-4","article-title":"New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders","volume":"482","author":"Quintanilla-Martinez","year":"2023","journal-title":"Virchows Archiv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.62.4.1442-1447.1988","article-title":"Characterization of a T-lymphocyte Epstein-Barr virus\/C3d receptor (CD21)","volume":"62","author":"Fingeroth","year":"1988","journal-title":"J Virol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.14.4510","article-title":"Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2","volume":"81","author":"Fingeroth","year":"1984","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90216-9","article-title":"Epstein-Barr virus gp350\/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis","volume":"50","author":"Tanner","year":"1987","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.17.6498","article-title":"Mutually exclusive use of viral promoters in Epstein-Barr virus latently infected lymphocytes","volume":"86","author":"Woisetschlaeger","year":"1989","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00226-19","article-title":"RNA sequencing analyses of gene expression during epstein-barr virus infection of primary B lymphocytes","volume":"93","author":"Wang","year":"2019","journal-title":"J Virol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0042-6822(91)90893-G","article-title":"Early events in Epstein-Barr virus infection of human B lymphocytes","volume":"181","author":"Alfieri","year":"1991","journal-title":"Virology"},{"key":"B17","article-title":"Epstein-Barr virus and its replication","volume":"1996","author":"Kieff","year":"1996","journal-title":"Field\u2019s Virol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004656","article-title":"To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis","volume":"11","author":"Price","year":"2015","journal-title":"PloS Pathog"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-599951","article-title":"The tumor virus landscape of AIDS-related lymphomas","volume":"125","author":"Arvey","year":"2015","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.50.11.911","article-title":"Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas","volume":"50","author":"Brink","year":"1997","journal-title":"J Clin Pathol"},{"key":"B21","article-title":"Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders","volume":"147","author":"Oudejans","year":"1995","journal-title":"Am J Pathol"},{"key":"B22","article-title":"Infection of leukaemic B lymphocytes by Epstein Barr virus","volume":"7","author":"Doyle","year":"1993","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00048-0","article-title":"EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency","volume":"13","author":"Kurth","year":"2000","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/embj.1987.6.issue-9","article-title":"Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt\u2019s lymphoma cells","volume":"6","author":"Rowe","year":"1987","journal-title":"EMBO J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein-Barr virus and the origins of associated lymphomas","volume":"350","author":"Thorley-Lawson","year":"2004","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-3-642-56352-2_2","article-title":"Clinicopathologic characteristics of post-transplant lymphoproliferative disorders","volume":"159","author":"Nalesnik","year":"2002","journal-title":"Recent Results Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1101\/gad.276568.115","article-title":"Role of TET enzymes in DNA methylation, development, and cancer","volume":"30","author":"Rasmussen","year":"2016","journal-title":"Genes Dev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001048","article-title":"CTCF prevents the epigenetic drift of EBV latency promoter Qp","volume":"6","author":"Tempera","year":"2010","journal-title":"PloS Pathog"},{"key":"B30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1515\/BC.2001.083","article-title":"Epigenetics of latent Epstein-Barr virus genomes: high resolution methylation analysis of the bidirectional promoter region of latent membrane protein 1 and 2B genes","volume":"382","author":"Takacs","year":"2001","journal-title":"Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.4.2969-2974.1998","article-title":"Specific methylation patterns in two control regions of Epstein-Barr virus latency: the LMP-1-coding upstream regulatory region and an origin of DNA replication (oriP)","volume":"72","author":"Falk","year":"1998","journal-title":"J Virol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05923-11","article-title":"Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency","volume":"86","author":"Hughes","year":"2012","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-4598-6-3","article-title":"Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt\u2019s lymphoma Akata cells","volume":"6","author":"Rao","year":"2007","journal-title":"Mol Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004126","article-title":"Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy","volume":"135","author":"Dalton","year":"2020","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.63.7.3135-3141.1989","article-title":"5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt\u2019s lymphoma line rael","volume":"63","author":"Masucci","year":"1989","journal-title":"J Virol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-0724-y","article-title":"DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression","volume":"5","author":"Guo","year":"2020","journal-title":"Nat Microbiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00804-17","article-title":"Coordinate regulation of TET2 and EBNA2 controls the DNA methylation state of latent epstein-barr virus","volume":"91","author":"Lu","year":"2017","journal-title":"J Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.292","article-title":"Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets","volume":"4","author":"Liu","year":"2023","journal-title":"MedComm (2020)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13223-018-0259-4","article-title":"Histone modifications and their role in epigenetics of atopy and allergic diseases","volume":"14","author":"Alaskhar Alhamwe","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2012.06.008","article-title":"An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions","volume":"12","author":"Arvey","year":"2012","journal-title":"Cell Host Microbe"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01396-07","article-title":"Acetylated histone H3 and H4 mark the upregulated LMP2A promoter of Epstein-Barr virus in lymphoid cells","volume":"81","author":"Gerle","year":"2007","journal-title":"J Virol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02172-06","article-title":"Chromatin profiling of Epstein-Barr virus latency control region","volume":"81","author":"Day","year":"2007","journal-title":"J Virol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/v5041042","article-title":"Interpreting the Epstein-Barr Virus (EBV) epigenome using high-throughput data","volume":"5","author":"Arvey","year":"2013","journal-title":"Viruses"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06768-11","article-title":"Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells","volume":"86","author":"Murata","year":"2012","journal-title":"J Virol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06334-11","article-title":"Dynamic chromatin environment of key lytic cycle regulatory regions of the Epstein-Barr virus genome","volume":"86","author":"Ramasubramanyan","year":"2012","journal-title":"J Virol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/v5051346","article-title":"The chromatin landscape of Kaposi\u2019s sarcoma-associated herpesvirus","volume":"5","author":"Toth","year":"2013","journal-title":"Viruses"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001013","article-title":"Epigenetic analysis of KSHV latent and lytic genomes","volume":"6","author":"Toth","year":"2010","journal-title":"PloS Pathog"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.1.430","article-title":"Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter","volume":"97","author":"Wang","year":"2000","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1317608110","article-title":"Epstein-Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2","volume":"110","author":"Portal","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002180","article-title":"EBV latency types adopt alternative chromatin conformations","volume":"7","author":"Tempera","year":"2011","journal-title":"PloS Pathog"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2015.33","article-title":"CTCF as a multifunctional protein in genome regulation and gene expression","volume":"47","author":"Kim","year":"2015","journal-title":"Exp Mol Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00755-18","article-title":"PARP1 stabilizes CTCF binding and chromatin structure to maintain epstein-barr virus latency type","volume":"92","author":"Lupey-Green","year":"2018","journal-title":"J Virol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpb.2016.05.001","article-title":"Functions of PARylation in DNA damage repair pathways","volume":"14","author":"Wei","year":"2016","journal-title":"Genomics Proteomics Bioinf"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00635-15","article-title":"Global transcriptome analysis reveals that poly(ADP-ribose) polymerase 1 regulates gene expression through EZH2","volume":"35","author":"Martin","year":"2015","journal-title":"Mol Cell Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174162","article-title":"PARP1: liaison of chromatin remodeling and transcription","volume":"14","author":"Zong","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2017.04.006","article-title":"PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter","volume":"507","author":"Lupey-Green","year":"2017","journal-title":"Virology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0801273105","article-title":"CTCF physically links cohesin to chromatin","volume":"105","author":"Rubio","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B58","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/nature06634","article-title":"Cohesin mediates transcriptional insulation by CCCTC-binding factor","volume":"451","author":"Wendt","year":"2008","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2008.1","article-title":"Cohesins localize with CTCF at the KSHV latency control region and at cellular c-myc and H19\/Igf2 insulators","volume":"27","author":"Stedman","year":"2008","journal-title":"EMBO J"},{"key":"B60","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0092-8674(01)80007-6","article-title":"Cohesins: chromosomal proteins that prevent premature separation of sister chromatids","volume":"91","author":"Michaelis","year":"1997","journal-title":"Cell"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/genes9120581","article-title":"The emerging role of cohesin in the DNA damage response","volume":"9","author":"Litwin","year":"2018","journal-title":"Genes (Basel)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16362","article-title":"Full circle: a brief history of cohesin and the regulation of gene expression","volume":"290","author":"Horsfield","year":"2023","journal-title":"FEBS J"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.201800108","article-title":"BZLF1 interacts with chromatin remodelers promoting escape from latent infections with EBV","volume":"2","author":"Schaeffner","year":"2019","journal-title":"Life Sci Alliance"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002902","article-title":"BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression","volume":"8","author":"Woellmer","year":"2012","journal-title":"PloS Pathog"},{"key":"B65","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/nar\/gkab1183","article-title":"Structural basis of DNA methylation-dependent site selectivity of the Epstein-Barr virus lytic switch protein ZEBRA\/Zta\/BZLF1","volume":"50","author":"Bernaudat","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-551","article-title":"Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes","volume":"2","author":"Heslop","year":"1996","journal-title":"Nat Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-863654","article-title":"EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation","volume":"132","author":"McLaughlin","year":"2018","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021782","article-title":"Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)","volume":"108","author":"Savoldo","year":"2006","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.18.10391","article-title":"Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease","volume":"96","author":"Khanna","year":"1999","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00854.x","article-title":"Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells","volume":"5","author":"Comoli","year":"2005","journal-title":"Am J Transplant"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281873","article-title":"Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes","volume":"116","author":"Barker","year":"2010","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20188","article-title":"Adoptive immunotherapy with allogeneic Epstein\u2013Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease","volume":"100","author":"Lucas","year":"2004","journal-title":"Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-091280","article-title":"Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer","volume":"110","author":"Bollard","year":"2007","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin\u2019s disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J Exp Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0574","article-title":"Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors","volume":"18","author":"Wildeman","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29698","article-title":"Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir","volume":"138","author":"Hui","year":"2016","journal-title":"Int J Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.canlet.2006.03.022","article-title":"Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir","volume":"247","author":"Jung","year":"2007","journal-title":"Cancer Lett"},{"key":"B83","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.bcmd.2006.10.008","article-title":"Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents","volume":"38","author":"Ghosh","year":"2007","journal-title":"Blood Cells Mol Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-362434","article-title":"Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents","volume":"119","author":"Ghosh","year":"2012","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1006\/bcmd.1998.0178","article-title":"Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma","volume":"24","author":"Mentzer","year":"1998","journal-title":"Blood Cells Mol Dis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid Malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010330","article-title":"Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid Malignancies: a phase 1b\/2 study","volume":"7","author":"Haverkos","year":"2023","journal-title":"Blood Adv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1342455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T23:26:31Z","timestamp":1708644391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1342455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2024.1342455"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1342455","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"article-number":"1342455"}}